Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2025-03-10 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
2024年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the "2024 年度财务决算报告" which translates to "2024 Annual Financial Settlement Report". It contains detailed financial data for the full year 2024, including income statement, balance sheet, cash flow analysis, and explanations of financial changes compared to previous years. The document mentions an audit by an accounting firm with an unqualified opinion, indicating it is a full audited annual financial report. The length is over 5,000 characters and contains substantive financial data and analysis, not just an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-03-10 Chinese
华泰联合证券有限责任公司关于新天地药业股份有限公司2024年年度跟踪报告
Audit Report / Information Classification · 90% confidence The document is titled as a "2024 Annual Tracking Report" by a sponsoring institution (华泰联合证券有限责任公司) regarding a company (新天地药业股份有限公司). It details the sponsor's review and supervision activities, compliance with regulations, company governance, and other oversight matters. It does not contain full financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a report on the sponsor's monitoring and compliance work related to the company, which aligns with the nature of an Audit Report / Information (AR) or a similar regulatory oversight report. Given the detailed supervisory content and absence of direct financial statements, the best fit is Audit Report / Information (AR). The document length (6082 characters) supports it being a substantive report rather than a brief announcement or certification. FY 2024
2025-03-10 Chinese
关于召开2024年年度股东会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of 新天地药业股份有限公司, including the date, time, location, voting procedures, agenda items, and instructions for shareholders. It contains no financial statements or detailed financial analysis but focuses on the logistics and agenda of the AGM. The document is over 6,000 characters and is not a brief announcement of a report publication but rather the official meeting notice. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or notices about the AGM itself.
2025-03-10 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company, detailing the approval of various reports and proposals related to the 2024 fiscal year, including the annual report, supervisory board work report, financial statements, internal control report, fundraising usage report, profit distribution plan, remuneration, auditor appointment, cash management, credit application, related party transactions, and independent director independence report. The document repeatedly states that the detailed reports are disclosed separately on a public information website (cninfo.com.cn) and that these resolutions will be submitted to the shareholders' meeting for approval. The document length is 4306 characters, which is relatively short and mainly serves as a meeting resolution announcement rather than containing the full reports themselves. According to the "Menu vs Meal" rule, this is an announcement of resolutions and references to reports rather than the reports themselves. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement of meeting resolutions and references to other filings, not the full annual report or other detailed reports.
2025-03-10 Chinese
关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (致同会计师事务所) as the company's auditor for the fiscal year 2025. It details the auditor's qualifications, independence, audit fees, and the approval process by the board and audit committee. There are no actual financial statements or audit reports included, only information about the appointment process and auditor credentials. The document length is relatively short (2513 characters) and it serves as a formal announcement rather than a full audit report or annual report. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-10 Chinese
致同会计师事务所（特殊普通合伙）关于新天地药业股份有限公司2024年度募集资金存放与实际使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed report titled "关于新天地药业股份有限公司 2024 年度募集资金存放与实际使用情况" which translates to "Verification Report on the Deposit and Actual Use of Raised Funds of Xintiandi Pharmaceutical Co., Ltd. for 2024." It includes an auditor's verification report from a certified public accounting firm, detailed tables of fundraising amounts, usage, balances, investment projects, and compliance with regulatory guidelines related to the management and use of raised funds. The document references regulatory guidelines specifically about fundraising management and usage, and it is a specialized report on the use of capital raised by the company. This type of document is a standalone audit or verification report on fundraising capital usage, not a full annual report or earnings release. It is not a simple announcement or certification but contains substantive financial and compliance information about fundraising capital. Therefore, it fits the category of Audit Report / Information (AR). FY 2024
2025-03-10 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.